A Randomized Double-blind Placebo-Controlled Phase 2 Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy

Go Back to All Clinical Trials

A Randomized Double-blind Placebo-Controlled Phase 2 Study to Evaluate the Efficacy Safety Tolerability Pharmacokinetics and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy

Brief description of study

The main purpose of this study is to assess the effectiveness and safety of TAK-341 in adult subjects with multiple system atrophy. Multiple system atrophy is a rare disease of the brain that affects multiple functions of the body, including blood pressure, breathing, urinary function, and various body movements. TAK-341 has been tested in healthy human subjects who received single doses of TAK-341 and was found to be safe and well-tolerated.

Clinical Study Identifier: s22-01037

ClinicalTrials.gov Identifier: NCT05526391

Principal Investigator: Patricio Alejandro Millar Vernetti.

Other Investigator: Maria Alejandra Gonzalez-Duarte Briseno.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies